Full Press Release Details
makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets
Singapore - (October 14, 2025) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"),
a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today
announced that it has submitted a cash bid for an undisclosed sum with Michael Magnay and Rob Croxen of Alvarez and Marsal Europe
LLP who were appointed as joint administrators to TC BioPharm Limited ("TCBL") on October 2, 2025, in relation to a
potential acquisition of potentially synergistic assets of TCBL (the "Proposed Acquisition").
and CytoMed are both clinical stage biopharmaceutical companies engaged in the research and development of donor-derived allogeneic gamma
delta T cells for cancer treatment. TCBL has completed Phase I clinical trial, while CytoMed is currently conducting its Phase I ANGELICA
Trial in Singapore under an Investigational New Drug (IND) application, evaluating its proprietary chimeric antigen receptor (CAR) T
cells for a broad range of liquid and solid cancers.
Proposed Acquisition is intended to strengthen and deepen CytoMed's expertise and knowledge in using allogeneic cell therapies
for cancer treatment, enabling the Company to accelerate its commercialization timeline and advance its mission to provide affordable
therapeutic options for patients, especially for no-option patients with unmet needs from all over the world.
on our data, we believe there is encouraging potential in using donor-derived gamma delta T cells for cancer treatment,"
said Mr. Peter Choo, Chairman of CytoMed. "Our collaborator, MD Anderson Cancer Center (MDACC), recently published a paper highlighting
the promise of this approach, as referenced in our announcement dated October
2, 2025. We believe that this allogeneic therapy is also safe in high doses and is cost-effective to manufacture at scale."
Mr. Peter Choo added, "China reportedly took recent steps to boost cell therapies in its hospitals which augurs well for our developing
China strategy. Presently, CytoMed's mission is to leverage Southeast Asia's low-cost infrastructure to make cell
therapies accessible to more patients. By combining our technologies, CytoMed aims to develop affordable T effector cells to benefit
Proposed Acquisition represents CytoMed's second acquisition within approximately one year. As previously announced on October 3, 2024, we completed the asset acquisition of a licensed cord blood bank in Malaysia, one of only three licensed cord blood banks there.
That acquisition provides access to rare and precious cord blood as cost-free raw materials for our strategic expansion into a new class
of cord blood-derived therapeutics for auto-immune diseases and cancers due to its na ve cord properties.
Proposed Acquisition will be funded by internal resources. More information will be announced when available. Shareholders and investors
are advised to exercise caution when dealing in the Company's securities until further announcements are made.
CytoMed Therapeutics Limited (CytoMed)
in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development
agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies,
namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for
the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T
therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating
("X") @CytomedSG, on LinkedIn, and Facebook.
press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions
and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will,
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results
to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject
to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product
candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical
trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements
and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates
on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions
underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes
no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date
Therapeutics Limited
: Evelyn Tan, Chief Corporate Officer